This is the authors' abstract. We don't add key points for this paper.
Evidence is reviewed which indicates that pinaverium bromide (PB) relaxes gatrointestinal (GI) structures mainly by specifically inhibiting Ca +2 influx through potential‐dependent channels that exist on the surface membranes of smooth muscle cells. Its in vivo selectivity for the GI tract appears to be due mainly to its pharmacokinetic properties. Because of its low absorption, typical for quarternary ammonium compounds, and its efficient hepato‐biliary excertion, most of the orally‐administered dose of PB remains in the GI tract. Other mechanisms possibly related to its selectivity, and comparisons between the actions of PB and those Ca 2+ ‐antagonists, are also disussed. PB is the only Ca 2+ ‐antagonist currently registered for treatment of functional intestinal disorders (e.g., irritable bowel syndrome). A major advantage of orally‐administered PB is that it does not elicit adverse systemic (e.g., cardiovasular) side‐effects at doses that effectively relieve GI spasm, pain, and abnormal motility.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Christen et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: